Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by HarveyTwofaceon Apr 30, 2018 6:51am
168 Views
Post# 27957263

A LOT of insider trading lately - Good or bad?

A LOT of insider trading lately - Good or bad?According to Canadian Insider there has been a LOT of trading from insiders lately. It is good if they invest by exercising options, but I can't help to feel bad about them doing these transactions in a very bearish trading momentum (for ATE, that is). I annoys the hell outta me that we (although longs) can't see our own stock go up in valuation as long as there is this massive dumping of shares from (mainly) the directors.

Yes, I understand if the board of directors want to cash in a bit - but they had a better chance doing this right after the trial results March 19th, right?

Sure, would have looked bad then, but still looks just as bad now when posting that CEO news letter making the market happier about ATE future while dumping stocks in a bearish momentum. Does not signal honesty to us who doesn't have any options to exercise......................................

I know it may look like they are confident in their companys future by converting options into shares - I just don't like to see them doing it on this scale all at the same time lately.

Could this mean they are somewhat worried about the upcoming release of the secondary end-points and that this might move the share price even lower? Meaning this is their best chance to have some extra cash for themselves in a while?
Or could this mean they know there will be a much higher valuation of the sp in a very near future (a month after all their insider tradings are done) due to some good news release that will bring buyers back en masse, and higher trading volume? Or what?

I certainly believe that Antibe has a bright future - but some of these recent insider trades taste bad at the moment. In fact - to me they kind of stink :-(

What are your thoughts on this?

Antibe Therapeutics insider trading



Bullboard Posts